Everett Harris & Co. CA Buys 3,975 Shares of Novo Nordisk A/S (NYSE:NVO)

Everett Harris & Co. CA raised its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 0.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,120,923 shares of the company’s stock after buying an additional 3,975 shares during the period. Novo Nordisk A/S makes up 4.0% of Everett Harris & Co. CA’s portfolio, making the stock its 6th biggest position. Everett Harris & Co. CA owned about 0.13% of Novo Nordisk A/S worth $161,352,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Advisors Preferred LLC bought a new position in shares of Novo Nordisk A/S during the 2nd quarter valued at about $26,000. Winthrop Partners WNY LLC acquired a new position in shares of Novo Nordisk A/S in the third quarter worth about $28,000. Prime Capital Investment Advisors LLC acquired a new position in shares of Novo Nordisk A/S in the third quarter worth about $28,000. Valeo Financial Advisors LLC boosted its holdings in shares of Novo Nordisk A/S by 510.7% in the second quarter. Valeo Financial Advisors LLC now owns 629 shares of the company’s stock worth $32,000 after buying an additional 526 shares during the period. Finally, Wealthcare Advisory Partners LLC boosted its holdings in shares of Novo Nordisk A/S by 75.6% in the second quarter. Wealthcare Advisory Partners LLC now owns 864 shares of the company’s stock worth $44,000 after buying an additional 372 shares during the period. 7.35% of the stock is currently owned by hedge funds and other institutional investors.

Several analysts recently commented on the stock. Pareto Securities upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Monday, August 5th. Jefferies Financial Group cut shares of Novo Nordisk A/S from a “hold” rating to an “underperform” rating in a report on Friday, August 30th. Bank of America raised their price target on shares of Novo Nordisk A/S from $355.00 to $400.00 and gave the stock a “neutral” rating in a report on Friday, September 13th. Citigroup upgraded shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a report on Tuesday, September 17th. Finally, ValuEngine upgraded shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating in a report on Friday, November 1st. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and six have issued a buy rating to the stock. Novo Nordisk A/S has a consensus rating of “Hold” and an average price target of $159.65.

Shares of NVO stock traded up $0.56 during trading on Wednesday, hitting $57.65. 40,410 shares of the company were exchanged, compared to its average volume of 1,409,626. The company has a debt-to-equity ratio of 0.06, a quick ratio of 0.73 and a current ratio of 1.00. The firm has a market capitalization of $135.92 billion, a price-to-earnings ratio of 22.86, a P/E/G ratio of 2.33 and a beta of 0.61. The business’s 50-day simple moving average is $53.44 and its 200 day simple moving average is $50.74. Novo Nordisk A/S has a twelve month low of $43.12 and a twelve month high of $57.93.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Friday, November 1st. The company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.62 by $0.02. The business had revenue of $4.51 billion during the quarter, compared to analysts’ expectations of $4.55 billion. Novo Nordisk A/S had a net margin of 32.44% and a return on equity of 75.48%. On average, equities analysts forecast that Novo Nordisk A/S will post 2.45 earnings per share for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

Recommended Story: CD Ladder

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.